| A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) (NCT05392114) | Ionis Pharmaceuticals, Inc. | 2022-07-13 |
| A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema (NCT04957641) | Takeda | 2022-04-21 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (NCT05047185) | Pharvaris Netherlands B.V. | 2022-04-19 |
| A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) (NCT05259917) | KalVista Pharmaceuticals, Ltd. | 2022-02-22 |
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (NCT05121376) | BioMarin Pharmaceutical | 2022-02-15 |
| NTLA-2002 in Adults With Hereditary Angioedema (HAE) (NCT05120830) | Intellia Therapeutics | 2021-12-10 |
| OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) (NCT05139810) | Ionis Pharmaceuticals, Inc. | 2021-12-03 |
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema (NCT04898309) | AO GENERIUM | 2021-12-01 |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (NCT04933721) | BioCryst Pharmaceuticals | 2021-07-23 |
| Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema (NCT04888650) | University Hospital, Grenoble | 2021-05-03 |
| Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks (NCT04739059) | CSL Behring | 2021-03-29 |
| Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema (NCT04687137) | Takeda | 2021-02-10 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (NCT04618211) | Pharvaris Netherlands B.V. | 2021-02-03 |
| CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks (NCT04656418) | CSL Behring | 2021-01-27 |
| A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema (NCT04654351) | Takeda | 2021-01-15 |
| Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations (NCT05118958) | KalVista Pharmaceuticals, Ltd. | 2020-05-19 |
| An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema (NCT04307381) | Ionis Pharmaceuticals, Inc. | 2020-03-31 |
| Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers (NCT04557319) | AO GENERIUM | 2020-03-10 |
| A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema (NCT04030598) | Ionis Pharmaceuticals, Inc. | 2020-01-07 |
| Hereditary Angioedema Kininogen Assay (NCT04091113) | CENTOGENE GmbH Rostock | 2019-09-01 |
| A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children (NCT04070326) | Shire | 2019-08-19 |
| A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II (NCT04208412) | KalVista Pharmaceuticals, Ltd. | 2019-07-02 |
| A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers (NCT05178355) | KalVista Pharmaceuticals, Ltd. | 2019-02-12 |
| A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) (NCT03712228) | CSL Behring | 2018-10-29 |
| Biomarker for Hereditary AngioEdema Disease (NCT03029728) | CENTOGENE GmbH Rostock | 2018-08-20 |
| Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) (NCT06690047) | Bernstein Clinical Research Center | 2018-08-14 |
| Patient Registry to Evaluate the Real-world Safety of Ruconest® (NCT03697187) | Pharming Technologies B.V. | 2018-06-30 |
| A Long Term Safety Study of BCX7353 in Hereditary Angioedema (NCT03472040) | BioCryst Pharmaceuticals | 2018-02-16 |
| A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers (NCT04349800) | KalVista Pharmaceuticals, Ltd. | 2018-01-04 |
| A Relative Bioavailability Study of Two Formulations of BCX7353 (NCT03202784) | BioCryst Pharmaceuticals | 2017-02-27 |
| A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions (NCT03136237) | BioCryst Pharmaceuticals | 2017-02-17 |
| An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates (NCT02819102) | BioCryst Pharmaceuticals | 2016-03-01 |
| Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population (NCT02854397) | University Hospital, Grenoble | 2016-02-15 |
| Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema (NCT02670720) | BioCryst Pharmaceuticals | 2015-12-01 |
| First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers (NCT02448264) | BioCryst Pharmaceuticals | 2015-05-01 |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks (NCT02303626) | BioCryst Pharmaceuticals | 2014-12-17 |
| Hereditary AngioEdema, Neurobiology and Psychopathology (NCT02159430) | University Hospital, Catania | 2014-11-01 |
| Study to Determine How BCX4161 is Metabolized and Eliminated by the Body (NCT02218294) | BioCryst Pharmaceuticals | 2014-08-01 |
| A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 (NCT02125162) | BioCryst Pharmaceuticals | 2014-04-01 |
| Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE (NCT01984788) | BioCryst Pharmaceuticals | 2013-11-01 |
| A Call Center During HAE Attacks (SOS HAE) (NCT01679912) | Assistance Publique - Hôpitaux de Paris | 2013-03-01 |
| Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients (NCT01359969) | Pharming Technologies B.V. | 2012-01-17 |
| Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE (NCT01457430) | Massachusetts General Hospital | 2011-12-01 |
| A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase (NCT01426763) | Shire | 2011-09-12 |
| C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks (NCT01397864) | Pharming Technologies B.V. | 2011-07-01 |
| C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation (NCT01151735) | Penn State University | 2010-07-01 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration (NCT01095497) | Shire | 2010-06-07 |
| EASSI - Evaluation of the Safety of Self-Administration With Icatibant (NCT00997204) | Shire | 2009-09-25 |
| A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (NCT00914966) | Shire | 2009-08-31 |
| A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) (NCT00912093) | Shire | 2009-07-16 |
| A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (NCT00851409) | Pharming Technologies B.V. | 2009-06-01 |
| Berinert P Study of Subcutaneous Versus Intravenous Administration (NCT00748202) | Johann Wolfgang Goethe University Hospital | 2008-09-01 |
| Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects (NCT00432510) | Shire | 2006-10-09 |
| Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks (NCT00462709) | Shire | 2006-06-27 |
| C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) (NCT00292981) | CSL Behring | 2005-08-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (NCT00225147) | Pharming Technologies B.V. | 2005-07-01 |
| Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks (NCT00168103) | CSL Behring | 2005-06-01 |
| C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks (NCT00289211) | Shire | 2005-03-14 |
| C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks (NCT01005888) | Shire | 2005-03-14 |
| Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) (NCT00500656) | Shire | 2005-03-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (NCT00262301) | Pharming Technologies B.V. | 2004-06-01 |
| Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat (NCT06628713) | KalVista Pharmaceuticals, Ltd. | |
| Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat (NCT07216378) | KalVista Pharmaceuticals, Ltd. | |
| Oral Berotralstat Expanded Access Program (NCT04428632) | BioCryst Pharmaceuticals | |
| Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema (NCT06415448) | Ionis Pharmaceuticals, Inc. | |
| EAP for Deucrictibant Immediate-release (NCT07759141) | Pharvaris Netherlands B.V. | |